Author Archives for Atlanpole Biotherapies

Interview with Olivier Boisteau – Vice-President of Clean Biologics and of Atlanpole Biotherapies.

30 November 2021

Leader of a group of over 200 people at Clean Biologics, a company offering a range of high-tech services to... View Article

New member | Inovalys

30 November 2021

Inovalys is a public laboratory which operates over a geographical area covering the Pays de la Loire, the Centre of... View Article

OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

30 November 2021

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) presented preclinical efficacy data for novel agonist monoclonal antibody therapy, OSE-230, at the 2020... View Article

New dental health application for Hemarina’s M101 molecule published in Scientific Reports research journal

30 November 2021

This demonstration of anti-inflammatory and anti-bacterial properties for treatment of periodontitis validates Hemarina’s technological platform based on the oxygenating molecule... View Article

Valneva Announces Major COVID-19 Vaccine Partnership with the U.K. Government

30 November 2021

UK Government has secured supply of 60 million doses at a cost of €470 million with options over another 130 million... View Article

Jessica Walker is joining Atlanpole Biotherapies as European Project Manager

30 November 2021

Jessica Walker is joining Atlanpole Biotherapies as European Project Manager. She will be working primarily on 3 European projects: CE4BIG,... View Article

HealthTech Innovation Days Announce Details of Conference Program & Attendees

30 November 2021

With strong support from the healthtech ecosystem shown by sponsors renewing their participation from last edition and additional newcomers eager... View Article

New member | SELHA GROUP

30 November 2021

SELHA GROUP is an industrial group expert in electronics. Located in France & Morocco, SELHA GROUP is specialized in design,... View Article

Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million

30 November 2021

Saint Herblain (France), September 9, 2020 – Valneva SE (“Valneva”), a specialty vaccine company, today announced the signing of a new contract, lasting... View Article

OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT

30 November 2021

Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory... View Article